Effect of TKI Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation on Recurrence of Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia p190 and p210 Transcripts: A Multicentre Study

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-01-07 DOI:10.1016/j.clml.2024.12.014

Jiayi Zhen , Shuping Lai , Xiangzhong Zhang , Lijun Huang , Ping Li , Yue Lin , Duorong Xu , Ganlin He

{"title":"Effect of TKI Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation on Recurrence of Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia p190 and p210 Transcripts: A Multicentre Study","authors":"Jiayi Zhen , Shuping Lai , Xiangzhong Zhang , Lijun Huang , Ping Li , Yue Lin , Duorong Xu , Ganlin He","doi":"10.1016/j.clml.2024.12.014","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To analyze the impact of tyrosine kinase inhibitor (TKI) maintenance therapy following allogeneic hematopoietic stem cell transplantation (HSCT) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) on recurrence rates and prognosis for the 2 transcripts, p190 and p210.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of clinical data from 58 patients diagnosed with Ph + ALL who underwent HSCT. All patients received TKI maintenance therapy following hematopoietic reconstruction post-transplantation. We compared the clinical characteristics and prognostic differences between 2 transcript types: p190 (<em>n</em> = 43) and p210 (<em>n</em> = 15).</div></div><div><h3>Result</h3><div>In terms of clinical characteristics, no significant differences were observed between patients with the 2 transcripts. Multivariate analysis revealed that the T3151 mutation (HR = 5.021, 95% CI [1.129-22.3], <em>P</em> = .034) was an independent risk factor for relapse-free survival (RFS) post-transplantation. Additionally, TKI maintenance therapy for over 1 year was identified as a protective factor for RFS (HR = 0.315, 95% CI [0.115-0.86], <em>P</em> = .025). The median RFS was 89.4 months for the p190 group compared to 59.1 months for the p210 group, which was statistically significant (<em>P</em> = .031). In the subgroup with more than 1 year of TKI maintenance therapy, the median RFS times for p190 and p210 were 95.3 and 90.5 months, respectively, with no statistically significant difference in RFS (<em>P</em> = .080).</div></div><div><h3>Conclusion</h3><div>The p190 group demonstrated longer RFS compared to the p210 group. However, with early HSCT following induction remission and long-term TKI maintenance therapy post-transplant, the poor prognosis associated with p210 could be mitigated, leading to a trend towards equivalence in outcomes between the 2 transcripts.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 5","pages":"Pages e282-e289"},"PeriodicalIF":2.7000,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2152265024024637","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To analyze the impact of tyrosine kinase inhibitor (TKI) maintenance therapy following allogeneic hematopoietic stem cell transplantation (HSCT) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) on recurrence rates and prognosis for the 2 transcripts, p190 and p210.

Methods

We conducted a retrospective analysis of clinical data from 58 patients diagnosed with Ph + ALL who underwent HSCT. All patients received TKI maintenance therapy following hematopoietic reconstruction post-transplantation. We compared the clinical characteristics and prognostic differences between 2 transcript types: p190 (n = 43) and p210 (n = 15).

Result

In terms of clinical characteristics, no significant differences were observed between patients with the 2 transcripts. Multivariate analysis revealed that the T3151 mutation (HR = 5.021, 95% CI [1.129-22.3], P = .034) was an independent risk factor for relapse-free survival (RFS) post-transplantation. Additionally, TKI maintenance therapy for over 1 year was identified as a protective factor for RFS (HR = 0.315, 95% CI [0.115-0.86], P = .025). The median RFS was 89.4 months for the p190 group compared to 59.1 months for the p210 group, which was statistically significant (P = .031). In the subgroup with more than 1 year of TKI maintenance therapy, the median RFS times for p190 and p210 were 95.3 and 90.5 months, respectively, with no statistically significant difference in RFS (P = .080).

Conclusion

The p190 group demonstrated longer RFS compared to the p210 group. However, with early HSCT following induction remission and long-term TKI maintenance therapy post-transplant, the poor prognosis associated with p210 could be mitigated, leading to a trend towards equivalence in outcomes between the 2 transcripts.

查看原文本刊更多论文

异基因造血干细胞移植后TKI维持治疗对费城染色体阳性急性淋巴细胞白血病p190和p210转录物复发的影响：一项多中心研究

目的：分析费城染色体阳性急性淋巴细胞白血病（Ph + ALL）患者异体造血干细胞移植（HSCT）后酪氨酸激酶抑制剂（TKI）维持治疗对2个转录本p190和p210复发率和预后的影响。方法：我们对58例经HSCT诊断为Ph + ALL的患者的临床资料进行了回顾性分析。所有患者在移植后造血重建后均接受TKI维持治疗。我们比较了两种转录类型p190 （n = 43）和p210 （n = 15）的临床特征和预后差异。结果：在临床特征方面，两种转录本患者之间无显著差异。多因素分析显示，T3151突变（HR = 5.021, 95% CI [1.129-22.3], P = 0.034）是影响移植后无复发生存（RFS）的独立危险因素。此外，TKI维持治疗超过1年被确定为RFS的保护因素（HR = 0.315, 95% CI [0.115-0.86], P = 0.025）。p190组的中位RFS为89.4个月，而p210组为59.1个月，差异有统计学意义（P = 0.031）。在TKI维持治疗超过1年的亚组中，p190和p210的中位RFS时间分别为95.3个月和90.5个月，RFS差异无统计学意义（P = 0.080）。结论：与p210组相比，p190组RFS更长。然而，通过诱导缓解后的早期HSCT和移植后长期TKI维持治疗，p210相关的不良预后可以得到缓解，导致两种转录物之间的结果趋于相等。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.